What Was Experienced at the 9th Antifibrotic Drug Development Summit
As the first MASH approval and IPF Phase 3 wins reset efficacy benchmarks, the Antifibrotic Drug Development Summit served as the industry’s only forum that successfully translated these breakthroughs into actionable discovery and R&D strategies across fibrotic diseases.
Across 20+ expert-led sessions, participants explored how leaders were:
Leveraging Advances in Omics Technologies
Uncover novel targets by mapping fibroblast-immune crosstalk with single-cell and spatial transcriptomics, accelerating first-in-class mechanism discovery.
Designing a Preclinical Package
Optimize chronic fibrosis models endpoints to derisk candidates before IND, aligning with recent Boehringer Ingelheim’s Phase 3 trial design.
Advancing Imaging & Biomarkers
Replace biopsies with collagen PET tracers and proteomic panels to quantify fibrosis reversal and stratify F2-F3 MASH subpopulations for clinical trials.
Reversing Translation from Phase 2
Decode lessons from GRI Bio’s NKT cell therapy and Alentis’ anti-Claudin-1 mAbs to refine preclinical models and biomarker strategies for faster Phase 2b readiness.
Uncovering emerging Innovations
Explore ADCs, mRNA therapies, and pan-fibrotic mechanisms to compete in a landscape reshaped by Madrigal’s Resmetirom and Lilly’s $99M Mediar deal.
Unmissable 2025 Event Highlights:
Clinical Case Studies:
Learn from reverse-translated Phase 2 data to extract lessons on patient stratification and biomarker-driven endpoints and refine Phase 2 protocols to mirror successful trials, from GRI Bio (NKT cell therapy) and Alentis (anti-Claudin-1 mAbs).
Cross-Fibrosis Panels:
Debate on pan-antifibrotics to compare organ-specific vs. shared mechanisms and prioritize targets with the broadest commercial potential, with AbbVie, Gilead, and Novartis.
Deep-Dive Workshops:
Discover the optimal preclinical models for chronic and progressive fibrosis modeling, dive deeper into the mechanistic complexities of fibroblast biology across indications, and progress toward transforming pan-antifibrotics from fiction to fact.
Download the 2025 Full Event Guide:
- 80+ industry leaders from top pharma, biotech, and academic organisations
- Actionable strategies across IPF, MASH, kidney, cardiac, and gut fibrosis, all in one place
- Exclusive data from recent approvals and Phase 2 successes
- Cutting-edge science including spatial omics, ADCs, and collagen-targeted PET imaging with pioneers
- 8+ hours of tailored networking opportunities
2025 Attending Companies Included
Explore the 2025 Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.